Trial Profile
A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ADACCESS
- Sponsors HEXAL; Novartis; Sandoz
- 30 Jan 2023 According to Sandoz media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorization for a citrate-free high concentration formulation of adalimumab. The authorization includes all indications covered by the reference medicine: rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis and uvetis.
- 09 Nov 2021 Results of a pooled analysis of data from 4 phase I studies (study 101,102, 103 & 104) and 2 phase III studies (ADACCESS & ADMYRA) presented at the ACR Convergence 2021
- 05 Jun 2021 Results of a pooled analysis of data from 4 phase I studies (study 101,102, 103 & 104) and 2 phase III studies (ADACCESS & ADMYRA) assessing the local tolerance to formulations containing citrate bufferpresented at the 22nd Annual Congress of the European League Against Rheumatism